Products for Research Use Only
RegisterLogin

KI-ARv-03

CAT: 0804-HY-153718Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153718Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
KI-ARv-03 is a potent and selective ATP-competitive CDK9 inhibitor with an IC₅₀ of 0.15 μM (at 45 μM ATP), exhibiting over 130-fold selectivity against other CDKs (including CDK1-7). KI-ARv-03 reduces androgen receptor (AR) -driven transcription and proliferation in prostate cancer cells. KI-ARv-03 can be used for leukemia, pancreatic cancer, alveolar rhabdomyosarcoma (ARMS) and castration-resistant prostate cancer (CRPC) research. KI-ARv-03 is a ligand for target protein for PROTAC. KI-ARv-03 can be used to synthesize PROTAC KI-CDK9d-32[2].
CAS Number
2416873-72-6
UNSPSC
12352005
Target
CDK; c-Myc; Ligands for Target Protein for PROTAC
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CCCC1=NC2=CC=NN2C(N[C@H]3C[C@@H](CC3)N)=C1
Molecular Formula
C14H21N5
Molecular Weight
259.35
References & Citations
[1]Richters A, et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021 Feb 18;28 (2) :134-147.e14|[2]Toure MA, et al. Targeted degradation of CDK9 potently disrupts the MYC-regulated network. Cell Chem Biol. 2025 Apr 17;32 (4) :542-555.e10.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9

Related Products

CatalogName
HY-158105-01ARV-393
HY-16954-01ARV-825
HY-100972-01ARV-771
HY-100972RARV-771 (Standard)
HY-158331Gal-ARV-771
HY-161313-01DYB-03
HY-179611LP-03
HY-124644-011E7-03
HY-164425ENT-03
HY-18187Ki 23057

Alternative Products

CatalogName
GTR19275145-01KI-ARv-03
BA4655-10ARV-825
BA4656-5.1ARV-771
BA5849-5ARV-393
EPD71168-01ARV-471
MBS3613655-01ARV-110
GTR19260090-01ARV-T1
E1573-01ARV-766

Popular Products